Researchers from Longhorn Vaccines & Diagnostics LLC recently presented preclinical data for the novel unconjugated peptide vaccine LHNVD-201, which is being developed as a universal vaccine candidate for protection against different strains of influenza and COVID-19.
Gro Biosciences Inc. has presented successful proof-of-concept results in two preclinical programs for autoimmune disease and immunogenicity. The company’s genomically recoded organism (GRO) platform enables precise placement of non-standard amino acids (NSAAs) within a protein.
The Global Health Innovative Technology (GHIT) Fund has announced new investments in the development of a new prophylactic vaccine against malaria, a new anti-malarial drug, and product development projects against neglected tropical diseases.
Arialys Therapeutics Inc. launched this month with $58 million in seed funding, an experimental compound it is developing for autoimmune encephalitis and autoimmune psychosis, and high aspirations for its field. “Yes, I want to treat these patients, I want these patients to have a better life. But I also want drug discovery and development folks to think differently about discovering new drugs for the CNS,” Jay Lichter told BioWorld.
Toleranzia AB has begun a regulatory GLP-toxicology study of TOL-2, being developed for myasthenia gravis. Animals will receive daily doses of TOL-2 on multiple days to determine the safety and tolerability of TOL-2.
Phylex Biosciences Inc. has announced plans to pursue the development of a nanoparticle mRNA vaccine against the Nipah virus. Last year, the company published proof of principle for its second-generation nanoparticle mRNA vaccine against the SARS-CoV-2 delta virus.
Astellas Pharma Inc. and Mitobridge Inc. have synthesized stimulator of interferon genes protein (STING; TMEM173) antagonists reported to be useful for the treatment of autoimmune diseases, neurodegeneration, type I interferonopathy and Sjögren’s syndrome.
RSS
